Clinton, what’s the source for this? It appears to omit relevant material.Korlym® (mifepristone) 300 mg Tablets
Korlym is a glucocorticoid receptor antagonist that is indicated to control hyperglycemia associated with Cushing's syndrome, a rare, debilitating endocrine disorder. Cushing's syndrome is caused by prolonged exposure to elevated levels of glucocorticoids (hypercortisolism). The potent metabolic effects of excess cortisol influence many tissues and body systems, and patients often have many problems, including diabetes, obesity, muscle wasting, depression, cognitive difficulties, and psychosis.
Korlym was launched in April 2012, and was the first FDA-approved oral therapy for the treatment of patients with endogenous Cushing's syndrome.
Korlym® (mifepristone) 300 mg Tablets
Korlym is a glucocorticoid receptor antagonist that is indicated to control hyperglycemia associated with Cushing's syndrome, a rare, debilitating endocrine disorder. Cushing's syndrome is caused by prolonged exposure to elevated levels of glucocorticoids (hypercortisolism). The potent metabolic effects of excess cortisol influence many tissues and body systems, and patients often have many problems, including diabetes, obesity, muscle wasting, depression, cognitive difficulties, and psychosis.
Korlym was launched in April 2012, and was the first FDA-approved oral therapy for the treatment of patients with endogenous Cushing's syndrome.
Biggest posting fail of the 24/7 so far this year. Congrats!Korlym® (mifepristone) 300 mg Tablets
Korlym is a glucocorticoid receptor antagonist that is indicated to control hyperglycemia associated with Cushing's syndrome, a rare, debilitating endocrine disorder. Cushing's syndrome is caused by prolonged exposure to elevated levels of glucocorticoids (hypercortisolism). The potent metabolic effects of excess cortisol influence many tissues and body systems, and patients often have many problems, including diabetes, obesity, muscle wasting, depression, cognitive difficulties, and psychosis.
Korlym was launched in April 2012, and was the first FDA-approved oral therapy for the treatment of patients with endogenous Cushing's syndrome.
Must have gone to the Kamala Harris school of editing.Biggest posting fail of the 24/7 so far this year. Congrats!
I googled Korylym and this was their statement:
Progesterone blocker
It can end a pregnancy that is less than 10 weeks along (70 days or fewer since the start of the last menstrual period). It can also control high blood sugar in patients with Cushing syndrome who have type 2 diabetes and have failed surgery or are not candidates for surgery.
It was a nice try though to leave out the Progesterone blocker portion of your description.
You even suck at using search engines haha.You googled corcept therapeutics.com?
http://www.corcept.com/korlym.html
Important Limitations of Use
Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome.
WARNING: TERMINATION OF PREGNANCY
Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. The antiprogestational effects will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with Korlym and prevented during treatment and for one month after stopping treatment by the use of a non-hormonal medically acceptable method of contraception unless the patient has had a surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females of reproductive potential.
“Fail”
Soooooo...what’s next for you sheep lol